Article
Author(s):
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2022.
Despite gout being largely associated with White men, new data suggest gout and hyperuricemia impart a larger burden on other demographic groups, including Black men, Black women, and White women.
Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.
Samsung Bioepis and Organon announced the US Food and Drug Administration (FDA) approval of the citrate-free, high-concentration (100 mg/mL) formulation of adalimumab-bwwd (HADLIMA), a biosimilar of adalimumab (HUMIRA), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and Crohn’s disease.
“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”
“These observations suggest that the often-observed epidemiologic correlation between low serum urate and adverse health outcomes may be confounded."